Order results by:
| Issue | Title | |
| Vol 19, No 2 (2026) | Biosimilar of the monoclonal antibody immunoglobulin G1κ daratumumab in treatment regimens for multiple myeloma patients | Abstract similar documents |
| M. M. Pankrashkina, A. L. Neverova, S. G. Malakho, E. S. Mikhailov, E. V. Naumova, E. I. Tikhonova | ||
| "... and budget impact analyses were conducted within a 1-year timeframe for the considered treatment strategies ..." | ||
| Vol 19, No 1 (2026) | Budget impact analysis of acalabrutinib plus venetoclax in chronic lymphocytic leukemia | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... Objective: To evaluate the budget impact of a fixed-duration combination (FC) “acalabrutinib ..." | ||
| Vol 19, No 2 (2026) | Pharmacoeconomic evaluation of triple beclomethasone/glycopyrronium bromide/formoterol combination in the treatment of patients with moderate and severe chronic obstructive pulmonary disease | Abstract similar documents |
| A. D. Ermolaeva, T. N. Ermolaeva, V. S. Krysanova, K. A. Kokushkin | ||
| "... , a budget impact analysis was carried out to evaluate the provision of triple FDCs in a single delivery ..." | ||
| Vol 19, No 1 (2026) | Administration of tyrosyl-D-arginyl-phenylalanyl-glycine amide to manage postoperative pain in patients with type 2 diabetes mellitus and obesity: budget impact analysis | Abstract similar documents |
| A. D. Ermolaeva, T. N. Ermolaeva, K. A. Kokushkin, A. M. Ovezov, S. O. Shkitin | ||
| "... health insurance system of Moscow Region. Material and methods. A pharmacoeconomic budget impact analysis ..." | ||
| Online First | Incretin-based therapy under pricing pressure: clinico-economic perspectives and role of biosimilar glucagon-like peptide-1 receptor agonists | Abstract similar documents |
| S. A. Kosobutskaya, D. Kh. Ausheva, M. A. Amirova, M. V. Belaya, S. A. Startseva, A. A. Samokhina, Ya. A. Vasileva, S. A. Kochetkova, B. P. Tsomaev, G. M. Dzgoev, N. T. Kokaeva, M. I. Sidakova, A. T. Kasaeva | ||
| Vol 19, No 2 (2026) | Use of real‑world evidence in comprehensive drug assessment | Abstract similar documents |
| F. V. Gorkavenko, V. V. Omelyanovskiy, A. V. Nikitina, A. A. Slabikova | ||
| "... -effectiveness analyses (CEAs) and budget impact analyses (BIAs) of drugs proposed for inclusion in 2018–2024 ..." | ||
| 1 - 6 of 6 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
